A5041084323- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- DNA Repair Mechanisms
- Pancreatic and Hepatic Oncology Research
- Genomics and Rare Diseases
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Lung Cancer Research Studies
- Statistical Methods in Clinical Trials
- RNA modifications and cancer
- Biomedical Ethics and Regulation
- Ferroptosis and cancer prognosis
- Economic and Financial Impacts of Cancer
- Monoclonal and Polyclonal Antibodies Research
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- RNA and protein synthesis mechanisms
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
Takeda (United States)
2024
BC Cancer Agency
2015-2024
Tris Pharma (United States)
2022-2024
McGill University
1994-2023
University of British Columbia
2017-2023
Health Net
2023
University Health Network
2023
Novartis (China)
2021
Spinal Cord Injury BC
2021
Novartis (United States)
2021
To site-specifically incorporate an unnatural amino acid (UAA) into target proteins in Escherichia coli, we use a suppressor plasmid that provides engineered tRNA and aminoacyl-tRNA synthetase (aaRS) specific for the UAA of interest. The continuous drive to further improve incorporation efficiency E. coli has resulted several generations plasmids. Here describe new, highly efficient plasmid, pUltra, harboring single copy each aaRS expression cassettes exhibits higher suppression activity...
The adoptive transfer of autologous T cells engineered to express a chimeric antigen receptor (CAR) has emerged as promising cancer therapy. Despite impressive clinical efficacy, the general application current CAR-T--cell therapy is limited by serious treatment-related toxicities. One approach improve safety CAR-T involves making their activation and proliferation dependent upon adaptor molecules that mediate formation immunological synapse between target cell T-cell. Here, we describe...
Purpose: Recent studies have identified mutation signatures of homologous recombination deficiency (HRD) in over 20% breast cancers, as well pancreatic, ovarian, and gastric cancers. There is an urgent need to understand the clinical implications HRD signatures. Whereas BRCA1/2 mutations confer sensitivity platinum-based chemotherapies, it not yet clear whether can independently predict platinum response.Experimental Design: In this observational study, we sequenced tumor whole genomes (100×...
Recent advances are enabling delivery of precision genomic medicine to cancer clinics. While the majority approaches profile panels selected genes or hotspot regions, comprehensive data provided by whole-genome and transcriptome sequencing analysis (WGTA) present an opportunity align a much larger proportion patients therapies.Samples from 570 with advanced metastatic diverse types enrolled in Personalized OncoGenomics (POG) program underwent WGTA. DNA-based data, including mutations, copy...
Given the success of targeted agents in specific populations it is expected that some degree molecular biomarker testing will become standard care for many, if not all, cancers. To facilitate this, cancer centers worldwide are experimenting with "panel" sequencing selected mutations. Recent advances genomic technology enable generation genome-scale data sets individual patients. Recognizing risk, inherent panel sequencing, failing to detect meaningful somatic alterations, we sought establish...
Selective covalent bond formation at a protein-protein interface potentially can be achieved by genetically introducing into protein an appropriately "tuned" electrophilic unnatural amino acid that reacts with native nucleophilic residue in its cognate receptor upon complex formation. We have evolved orthogonal aminoacyl-tRNA synthetase/tRNACUA pairs encode three aza-Michael acceptor acids, N(ε)-acryloyl-(S)-lysine (AcrK, 1), p-acrylamido-(S)-phenylalanine (AcrF, 2), and...
Abstract Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid tumors with dramatic and durable responses seen across multiple tumor types. However, identifying patients who will respond to these drugs remains challenging, particularly in context advanced previously treated cancers. Experimental Design: We characterized fresh biopsies from a heterogeneous pan-cancer cohort 98 metastatic predominantly pretreated disease through Personalized OncoGenomics...
Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with advanced non–small-cell lung cancer (NSCLC) whose expression status positive or unknown. Although it efficacious, erlotinib can cause skin toxicity. This prospective, randomized phase III trial examined the effect of prophylactic treatment erlotinib-induced rash. Patients and Methods receiving in second- third-line setting NSCLC were randomly assigned to minocycline (100 mg twice per day 4 weeks),...
Structural variants (SVs) may be an underestimated cause of hereditary cancer syndromes given the current limitations short-read next-generation sequencing. Here we investigated utility long-read sequencing in resolving germline SVs susceptibility genes detected through genome sequencing.Known or suspected deleterious were identified using Illumina across a cohort 669 advanced patients with paired tumor and transcriptome Candidate subsequently assessed by Oxford Nanopore sequencing.Nanopore...
Air pollution may play an important role in the development of lung cancer people who have never smoked, especially among East Asian women. The aim this study was to compare cumulative ambient air exposure between ever and smokers with cancer.A consecutive case series newly diagnosed were compared regarding their sex, race, outdoor household exposure. Using individual residential history, particulate matter (PM2.5) a period 20 years quantified high-spatial resolution global model.Of 1005...
There is emerging evidence about the predictive role of homologous recombination deficiency (HRD), but this less defined in gastrointestinal (GI) and thoracic malignancies. We reviewed whole genome (WGS) transcriptomic (RNA-Seq) data from advanced GI cancers Personalized OncoGenomics trial (NCT02155621) to evaluate HRD scores single base substitution (SBS)3, which associated with BRCA1/2 mutations potentially defective HRD. were calculated by sum loss heterozygosity, telomeric allelic...
Assessing treatment effect heterogeneity (TEH) in clinical trials is crucial, as it provides insights into the variability of responses among patients, influencing important decisions related to drug development. Furthermore, can lead personalized medicine by tailoring treatments individual patient characteristics. This paper introduces novel methodologies for assessing effects using a basis. To estimate this effect, we use Double Robust (DR) learner infer pseudo-outcome that reflects causal...
Abstract The emerging use of immunotherapy for cancer treatment has led to a greater need characterizing markers response. Incorporating immune profiling tools into whole genome and transcriptome sequencing analysis (WGTA) pipelines facilitates the identification biomarkers response that may be used inform clinical trial design. Personalized OncoGenomics (POG) program enrolled >1,200 patients with advanced/metastatic cancers diverse histologies underwent WGTA, which allowed...